FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease

• Published in: Scientific reports Vol. 10; no. 1; p. 21655
• Main Authors: Januszewski, Andrzej S., Watson, Chris J., O’Neill, Vikki, McDonald, Kenneth, Ledwidge, Mark, Robson, Tracy, Jenkins, Alicia J., Keech, Anthony C., McClements, Lana
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10-12-2020; Nature Publishing Group; Nature Portfolio
• Subjects: 631/45; 692/163; 692/4017; 692/4019; 692/53; 692/699; Aged; Angiogenesis; Biomarkers; Blood pressure; Brain natriuretic peptide; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - physiopathology; Case-Control Studies; Cholesterol; Creatinine; Diabetes; Diabetes mellitus (non-insulin dependent); Double-Blind Method; Fasting; Female; Gender; Health risks; Humanities and Social Sciences; Humans; Male; Middle Aged; multidisciplinary; Peptides; Placebos; Prospective Studies; Randomized Controlled Trials as Topic; Science; Science (multidisciplinary); Tacrolimus; Tacrolimus Binding Proteins - physiology; Tacrolimus-binding protein
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-78676-6

Type 2 diabetes (T2D) is associated with increased risk of cardiovascular disease (CVD). As disturbed angiogenesis and endothelial dysfunction are strongly implicated in T2D and CVD, we aimed to investigate the association between a novel anti-angiogenic protein, FK506-binding protein like (FKBPL), and these diseases. Plasma FKBPL was quantified by ELISA cross-sectionally in 353 adults, consisting of 234 T2D and 119 non–diabetic subjects with/without CVD, matched for age, BMI and gender. FKBPL levels were higher in T2D (adjusted mean: 2.03 ng/ml ± 0.90 SD) vs. non-diabetic subjects (adjusted mean: 1.79 ng/ml ± 0.89 SD,
p
 = 0.02), but only after adjustment for CVD status. In T2D, FKBPL was negatively correlated with fasting blood glucose, HbA1c and diastolic blood pressure (DBP), and positively correlated with age, known diabetes duration, waist/hip ratio, urinary albumin/creatinine ratio (ACR) and fasting C-peptide. FKBPL plasma concentrations were increased in the presence of CVD, but only in the non-diabetic group (CVD: 2.02 ng/ml ± 0.75 SD vs. no CVD: 1.68 ng/ml ± 0.79 SD,
p
 = 0.02). In non-diabetic subjects, FKBPL was positively correlated with an established biomarker for CVD, B-type Natriuretic Peptide (BNP), and echocardiographic parameters of diastolic dysfunction. FKBPL was a determinant of CVD in the non-diabetic group in addition to age, gender, total-cholesterol and systolic blood pressure (SBP). FKBPL may be a useful anti-angiogenic biomarker in CVD in the absence of diabetes and could represent a novel CVD mechanism.